You are here:

Forthcoming Submission: guselkumab (Tremfya)

Indication: Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy

Drug Details

Drug Name: guselkumab (Tremfya)
Drug Manufacturer: Janssen-Cilag Ltd
BNF Category:
Submission type: Full submission
Patient Interest Group
Submission Deadline:
2/04/2018
SMC Meeting Date: 1/05/2018
Advice Due: 11/06/2018

Back